A pioneering new breast cancer treatment will not be routinely available in England and Wales, the NHS drugs advisory body NICE is proposing.
The drug – Kadcyla – adds six months of life on average to women dying with an aggressive form of breast cancer.
NICE criticised makers Roche for not setting an affordable price, in its updated draft guidance.
The drug costs £90,000 per patient but Roche said it had offered a lower – undisclosed – price in recent talks.
The two organisations have been in negotiations since the first draft guidance from NICE (the National Institute for Health and Care Excellence), rejecting the drug, was published in April.
Click on the link to read more
http://www.bbc.co.uk/news/health-28688311
Are you affected by the Kadcyla decision? Sensitive C4 documentary wants to hear from you. email : health@voltage.tu
Filed under: Uncategorized, Kadcyla, NHS, Roche
I’m so glad this has been highlighted. Read my post about the impact of the decision on me in my post http://hannahlouisehallblog.wordpress.com/2014/08/09/kadcyla-the-drug-that-can-help-you-live-longer/
LikeLike